The magnitude of early hepatitis B RNA and DNA declines directly inform capsid assembly modulator effectiveness
Abstract
Capsid assembly modulators (CAMs) are a promising class of antiviral treatments for hepatitis B virus (HBV) infection. Several CAMs have been evaluated in clinical trials but there is no simple method to estimate their in vivo antiviral effectiveness. We performed viral dynamics modeling of the intracellular and extracellular dynamics of HBV RNA, HBV DNA, and ALT during phase I trials of two CAMs, vebicorvir and ABI-H2158, which inhibit the encapsidation of pgRNA. Fitting our model to the data, we quantify the drug-induced percent inhibition of encapsidated pgRNA production, which we term their in vivo antiviral effectiveness. In both trials, the HBV RNA and HBV DNA declined in a biphasic manner during therapy. The model described these decays well and, by fitting the model to the data, we estimated the CAM effectiveness in each trial participant. Mathematical analysis of the model showed that the magnitude of the first phase of decline of HBV RNA and HBV DNA is explicitly related to CAM effectiveness. However, in the clinic, the end of the first phase may not be known due to sparse sampling. Using clinical trial simulations, we show that the HBV RNA and HBV DNA declines between baseline and day 14 of CAM monotherapy can be used to predict CAM effectiveness. We show that HBV RNA is a clinically relevant biomarker and that very short-term phase I clinical trials can be used to evaluate the in vivo effectiveness of new CAMs, thus reducing the danger of drug resistance…
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.